ESC 365 - Prognostic impact of vascular disease in patients with atrial fibrillation: Insights from The Loire Valley Atrial Fibrillation Project

EHRA Premium Access

Prognostic impact of vascular disease in patients with atrial fibrillation: Insights from The Loire Valley Atrial Fibrillation Project

Session: New on atrial fibrillation

Topic: Epidemiology, Prognosis, Outcome

Speaker: Doctor A. Fawzy (Liverpool, GB)

Event: EHRA 2022

Congress Presentation

About the speaker

Doctor Ameenathul Mazaya Fawzy

Liverpool Heart and Chest Hospital, Liverpool (United Kingdom of Great Britain & Northern Ireland)

1 presentation

0 follower

4 more presentations in this session

The 3S-AF scheme, rather than the 4S-AF scheme, predicts progression in patients with paroxysmal atrial fibrillation: data from RACE V study

Speaker: Doctor V. Artola (Groningen, NL)

Evolving changes of outcomes in patients with newly diagnosed atrial fibrillation: a nationwide study.

Speaker: Professor L. Fauchier (Tours, FR)

Incident arrhythmias, heart failure and cardiovascular outcomes with SGLT-2 inhibitor use in diabetic patients: Insights from a global federated electronic medical record database

Speaker: Doctor A. Fawzy (Liverpool, GB)

Atrial fibrillation is associated with an increased risk of ventricular arrhythmias and sudden death in the general population

Speaker: Doctor A. Fawzy (Liverpool, GB)

Access the full session

New on atrial fibrillation

Speakers: Doctor A. Fawzy, Doctor V. Artola, Professor L. Fauchier, Doctor A. Fawzy, Doctor A. Fawzy

About the event

EHRA 2022

3 April - 5 April 2022

Sessions Presentations

Congress

Related content

EHRA Premium Access

Effectiveness and safety of edoxaban in 27,333 patients from ETNA-AF with and without a history of intracranial haemorrhage after 2 years of treatment

4 April 2022

ESC Premium Access

Trajectories of high-sensitivity cardiac troponin I in the two decades before cardiovascular death in whitehall II

30 August 2021

Open Access

Panel Discussion: The case for combination therapy: The way forward in intensive LDL-c management?

27 August 2021

ESC 365 is supported by